{"id":"capecitabine-monotherapy","safety":{"commonSideEffects":[{"rate":"60","effect":"Hand-foot skin reaction (palmar-plantar erythrodysesthesia)"},{"rate":"55","effect":"Diarrhea"},{"rate":"35","effect":"Nausea"},{"rate":"25","effect":"Vomiting"},{"rate":"25","effect":"Stomatitis"},{"rate":"40","effect":"Fatigue"},{"rate":"25","effect":"Neutropenia"},{"rate":"5","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tumor-selective conversion to 5-fluorouracil (5-FU). Once activated, 5-FU inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also being incorporated into RNA to disrupt protein synthesis. This dual mechanism leads to cancer cell death, particularly in rapidly dividing cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:50.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07060807","phase":"PHASE3","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-21","conditions":"Breast Neoplasms","enrollment":1000},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":"Cancer","enrollment":1500},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT05489211","phase":"PHASE2","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-06","conditions":"Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":454},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT07417241","phase":"PHASE2","title":"SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT02000622","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-03-27","conditions":"Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation","enrollment":302},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT05985655","phase":"PHASE1, PHASE2","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","startDate":"2023-07-06","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":230},{"nctId":"NCT03516708","phase":"PHASE1, PHASE2","title":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-06","conditions":"Rectal Cancer","enrollment":49},{"nctId":"NCT07266025","phase":"PHASE2","title":"Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-01-30","conditions":"Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors","enrollment":30},{"nctId":"NCT07357623","phase":"PHASE2","title":"Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-09-22","conditions":"Pulmonary Neuroendocrine Tumor","enrollment":96},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":"Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, Breast Cancer","enrollment":297},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT04711824","phase":"PHASE1, PHASE2","title":"Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases","status":"RECRUITING","sponsor":"Colette Shen","startDate":"2022-03-09","conditions":"Breast Cancer, Brain Metastases, Adult","enrollment":41},{"nctId":"NCT07296666","phase":"PHASE2","title":"Adjuvant Chemotherapy for BTC Based on 3D-PTA","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12","conditions":"Cholangiocarcinoma","enrollment":98},{"nctId":"NCT05249101","phase":"PHASE1, PHASE2","title":"A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Pharmaceuticals, Inc","startDate":"2022-08-15","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":70},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT06764940","phase":"PHASE2","title":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","status":"RECRUITING","sponsor":"Biostar Pharma, Inc.","startDate":"2025-07-14","conditions":"HER2-negative Breast Cancer Patients With Brain Metastases","enrollment":120},{"nctId":"NCT02810743","phase":"PHASE3","title":"Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-01-25","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT05367635","phase":"PHASE1","title":"A Study of SKB315 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-03-16","conditions":"Advanced Solid Tumors","enrollment":246},{"nctId":"NCT05482893","phase":"PHASE1, PHASE2","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","status":"RECRUITING","sponsor":"Phanes Therapeutics","startDate":"2023-03-15","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)","enrollment":258},{"nctId":"NCT06544655","phase":"PHASE1","title":"A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-10-10","conditions":"Advanced Solid Tumors","enrollment":213},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT07134101","phase":"PHASE2","title":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Colorectal Cancer (Diagnosis)","enrollment":138},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT02872116","phase":"PHASE3","title":"Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-10-12","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma","enrollment":2031},{"nctId":"NCT07054879","phase":"","title":"CtDNA-guided Maintenance Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-01","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT01630083","phase":"PHASE2","title":"Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-19","conditions":"CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma","enrollment":252},{"nctId":"NCT07021261","phase":"PHASE3","title":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06-16","conditions":"Breast Cancer, TNBC","enrollment":440},{"nctId":"NCT04566380","phase":"PHASE2","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2020-09-10","conditions":"Pan-tumor","enrollment":59},{"nctId":"NCT05704985","phase":"PHASE1","title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"DEKA Biosciences","startDate":"2023-04-03","conditions":"Cancer, Solid Tumor, Colorectal Cancer","enrollment":39},{"nctId":"NCT03562637","phase":"PHASE3","title":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"OBI Pharma, Inc","startDate":"2018-12-05","conditions":"Triple Negative Breast Cancer","enrollment":575},{"nctId":"NCT06090994","phase":"PHASE4","title":"Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-18","conditions":"Colorectal Cancer","enrollment":756},{"nctId":"NCT04965688","phase":"PHASE2","title":"Biology Guided Therapy for Breast Cancer for ER Positive","status":"TERMINATED","sponsor":"Inova Health Care Services","startDate":"2021-08-08","conditions":"Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":2},{"nctId":"NCT06888843","phase":"PHASE2","title":"Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.","status":"RECRUITING","sponsor":"Nizhny Novgorod Regional Clinical Oncology Center","startDate":"2025-02-01","conditions":"Colorectal Cancer","enrollment":160},{"nctId":"NCT06892431","phase":"PHASE2","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic Nasopharyngeal Cancer, Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy","enrollment":150},{"nctId":"NCT06775236","phase":"PHASE1, PHASE2","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-20","conditions":"Advanced Solid Tumors, Breast Cancer","enrollment":410},{"nctId":"NCT06629597","phase":"PHASE3","title":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","startDate":"2024-12-31","conditions":"Nasopharyngeal Carcinoma","enrollment":400},{"nctId":"NCT04257461","phase":"PHASE3","title":"A Trial to Evaluate the Potential Benefit of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma","status":"UNKNOWN","sponsor":"Belgian Group of Digestive Oncology","startDate":"2020-02-20","conditions":"Small Bowel Adenocarcinoma","enrollment":30},{"nctId":"NCT02892123","phase":"PHASE1","title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2016-09-30","conditions":"HER2-expressing Cancers","enrollment":279},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT05034887","phase":"PHASE2","title":"Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients with HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-01-31","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT03901339","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-08","conditions":"Metastatic Breast Cancer","enrollment":543},{"nctId":"NCT06275958","phase":"PHASE3","title":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-07-01","conditions":"Older Patients, Colorectal Cancer, Metastatic Cancer","enrollment":587},{"nctId":"NCT06493760","phase":"PHASE2","title":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","status":"RECRUITING","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2024-09-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06469060","phase":"PHASE2","title":"Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-06-19","conditions":"Esophageal Cancer","enrollment":34},{"nctId":"NCT06368063","phase":"PHASE4","title":"The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Xi'an Jiaotong University","startDate":"2024-05-06","conditions":"Pancreatic Cancer Resectable","enrollment":642},{"nctId":"NCT06387368","phase":"PHASE4","title":"Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xi'an Jiaotong University","startDate":"2024-05","conditions":"Pancreatic Cancer Non-resectable","enrollment":488},{"nctId":"NCT05228431","phase":"PHASE2","title":"Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Zhen-Hai Lu","startDate":"2022-03-02","conditions":"Advanced Rectal Cancer","enrollment":121},{"nctId":"NCT06014372","phase":"PHASE2","title":"Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-01","conditions":"Colon Cancer, Neoadjuvant Therapy, Immunotherapy","enrollment":55},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT03756298","phase":"PHASE2","title":"Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2019-01-15","conditions":"Triple Negative Breast Cancer","enrollment":284},{"nctId":"NCT06055166","phase":"PHASE2","title":"A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-11-01","conditions":"PARP Inhibitor for Esophageal Squamous Cell Carcinoma","enrollment":120},{"nctId":"NCT06043999","phase":"NA","title":"Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Chemotherapy Effect, Rectal Cancer","enrollment":392},{"nctId":"NCT04894123","phase":"PHASE2","title":"Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients","status":"TERMINATED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2022-02-07","conditions":"Colorectal Adenocarcinoma, Oesogastric","enrollment":1},{"nctId":"NCT02611960","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-04-18","conditions":"Nasopharyngeal Neoplasms","enrollment":233},{"nctId":"NCT05799820","phase":"PHASE2","title":"QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2022-09-29","conditions":"Colorectal Carcinoma","enrollment":60},{"nctId":"NCT05833919","phase":"PHASE2","title":"Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2018-07-30","conditions":"Metastatic Breast Cancer","enrollment":122},{"nctId":"NCT02494583","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-31","conditions":"Gastric Adenocarcinoma","enrollment":763},{"nctId":"NCT05717764","phase":"PHASE3","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment","status":"NOT_YET_RECRUITING","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-02","conditions":"Recurrent Metastatic Nasopharyngeal Carcinoma","enrollment":500},{"nctId":"NCT03775525","phase":"PHASE1","title":"Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer","status":"UNKNOWN","sponsor":"Genzada Pharmaceuticals USA, Inc.","startDate":"2019-03-01","conditions":"Advanced Cancer, Gastric Cancer, Breast Cancer","enrollment":127},{"nctId":"NCT03383679","phase":"PHASE2","title":"Study on Androgen Receptor and Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2018-03-14","conditions":"Breast Cancer Female, Triple Negative and Androgen Receptor Positive","enrollment":94},{"nctId":"NCT05608785","phase":"PHASE1, PHASE2","title":"Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-01-01","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":45},{"nctId":"NCT03844256","phase":"PHASE1, PHASE2","title":"A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-01-07","conditions":"Urinary Bladder Cancer, Invasive Bladder Cancer","enrollment":50},{"nctId":"NCT02335411","phase":"PHASE2","title":"A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-03","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":318},{"nctId":"NCT03781362","phase":"PHASE1","title":"Study of CPI-100 in Patients With Advanced Tumors","status":"COMPLETED","sponsor":"Coordination Pharmaceuticals, Inc.","startDate":"2018-12-21","conditions":"Advanced Tumors","enrollment":36},{"nctId":"NCT05246982","phase":"PHASE2","title":"HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-03-23","conditions":"Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)","enrollment":40},{"nctId":"NCT05292742","phase":"PHASE2","title":"Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2021-07-02","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":206},{"nctId":"NCT04787354","phase":"PHASE3","title":"Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)","status":"RECRUITING","sponsor":"Hallym University Medical Center","startDate":"2021-11-01","conditions":"Gastric Cancer","enrollment":976},{"nctId":"NCT05198856","phase":"PHASE1, PHASE2","title":"Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-10","conditions":"Gastric Cancer Metastatic to Liver","enrollment":106},{"nctId":"NCT00640081","phase":"PHASE2","title":"Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Cheryl Pugh","startDate":"2007-07","conditions":"Colorectal Cancer","enrollment":169},{"nctId":"NCT02948348","phase":"PHASE1, PHASE2","title":"Study to Nivolumab Following Preoperative Chemoradiotherapy","status":"UNKNOWN","sponsor":"Takayuki Yoshino","startDate":"2016-10","conditions":"Cancer of Rectum","enrollment":90},{"nctId":"NCT02715531","phase":"PHASE1","title":"A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-06","conditions":"Solid Tumor","enrollment":243},{"nctId":"NCT04098796","phase":"PHASE2","title":"PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2019-10-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma, AFP","enrollment":30},{"nctId":"NCT03563170","phase":"PHASE1, PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":"Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent","enrollment":""},{"nctId":"NCT04780347","phase":"PHASE2","title":"Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-12-15","conditions":"Breast Cancer","enrollment":92},{"nctId":"NCT01783444","phase":"PHASE2","title":"A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-26","conditions":"Breast Cancer","enrollment":309},{"nctId":"NCT02114359","phase":"PHASE3","title":"Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2014-02","conditions":"Gastric Cancer","enrollment":111},{"nctId":"NCT01369433","phase":"NA","title":"A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols","status":"TERMINATED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2010-06","conditions":"Solid Tumors","enrollment":225},{"nctId":"NCT03817268","phase":"PHASE3","title":"Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Anhui Medical University","startDate":"2019-01-16","conditions":"Gastric Cancer","enrollment":768},{"nctId":"NCT02981342","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-01-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":106},{"nctId":"NCT01534546","phase":"PHASE3","title":"Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection","status":"UNKNOWN","sponsor":"Peking University","startDate":"2012-03","conditions":"Advanced Gastric Carcinoma","enrollment":1094},{"nctId":"NCT01234402","phase":"PHASE2","title":"Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-03","conditions":"Breast Cancer","enrollment":153},{"nctId":"NCT02418624","phase":"PHASE1","title":"Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2015-05","conditions":"Breast Cancer, Ovarian Cancer, Advanced Cancer","enrollment":25},{"nctId":"NCT03686254","phase":"PHASE2, PHASE3","title":"The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-07-16","conditions":"Colorectal Neoplasms Malignant","enrollment":160},{"nctId":"NCT03082053","phase":"PHASE1","title":"A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2017-01-31","conditions":"Advanced or Metastatic Biliary Tract Cancer, Advanced or Metastatic Solid Tumors","enrollment":24},{"nctId":"NCT00790816","phase":"PHASE1","title":"Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-10","conditions":"Neoplasms, Breast","enrollment":500},{"nctId":"NCT03423849","phase":"PHASE2, PHASE3","title":"The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy","status":"UNKNOWN","sponsor":"Zhiyong Yu","startDate":"2018-02-08","conditions":"Breast Cancer, Chemotherapy Effect, Disease-free Survival","enrollment":200},{"nctId":"NCT02479217","phase":"","title":"Safety of Xeloda in Solid Tumours","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-07","conditions":"Metastatic Breast Cancer, Colon Cancer","enrollment":1268},{"nctId":"NCT01718808","phase":"PHASE2","title":"Cetuximab for Elderly Patients With mCRC","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2012-11","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":210,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Capecitabine"],"phase":"phase_3","status":"active","brandName":"Capecitabine monotherapy","genericName":"Capecitabine monotherapy","companyName":"Zhen-Hai Lu","companyId":"zhen-hai-lu","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Metastatic colorectal cancer, Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}